Literature DB >> 12628213

Parkinson's disease and sleep.

Diego Garcia-Borreguero1, Oscar Larrosa, Mauricio Bravo.   

Abstract

Sleep disorders are common in Parkinson's disease (PD), as almost two thirds of PD patients report them. From a clinical point of view, they can be classified into disorders of initiation and maintenance of sleep (DIMS), parasomnias, and excessive daytime sleepiness (EDS). Among the causes of DIMS are degenerative changes in the CNS affecting centers for sleep regulation, persistence into the night of daytime PD-related symptoms, concomitant medical or psychiatric disease, disruption of circadian rhythms, and effects of dopaminergic (and other) medication on sleep regulation. Parasomnias might further contribute to sleep disturbance, as they can be accompanied by motor desinhibition during REM sleep. Parasomnias can precede by several years the presence of daytime PD symptoms. EDS has been over the last years the focus of attention for both sleep and movement disorders specialists, due to the fact that it might predispose to traffic accidents. However, the so-called "sleep attacks" never occur without preexisting somnolence. Thus, a careful sleep history can be helpful to determine which patients are exposed to suffer them. Although EDS was initially attributed to the effects of dopaminergic medication, it seems likely that several disease-related factors might also play an important role. An adequate education of the PD patients in sleep hygiene measures and a skilled use of the medication seem necessary to prevent sleep disturbance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628213     DOI: 10.1053/smrv.2002.0229

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  44 in total

1.  Circadian activity rhythms and mortality: the study of osteoporotic fractures.

Authors:  Gregory J Tranah; Terri Blackwell; Sonia Ancoli-Israel; Misti L Paudel; Kristine E Ensrud; Jane A Cauley; Susan Redline; Teresa A Hillier; Steven R Cummings; Katie L Stone
Journal:  J Am Geriatr Soc       Date:  2010-01-26       Impact factor: 5.562

2.  Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bienfait; Allison Dicke; Cynthia L Comella; Charles Cantor; Lee Hyer
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

3.  Risk of sleep-disordered breathing in Parkinson's disease.

Authors:  Wattanachai Chotinaiwattarakul; Praveen Dayalu; Ronald D Chervin; Roger L Albin
Journal:  Sleep Breath       Date:  2010-05-16       Impact factor: 2.816

4.  c-Jun N-terminal kinase inhibitor SP600125 modulates the period of mammalian circadian rhythms.

Authors:  M Chansard; P Molyneux; K Nomura; M E Harrington; C Fukuhara
Journal:  Neuroscience       Date:  2007-01-30       Impact factor: 3.590

5.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 6.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 7.  Sleep disturbances in Parkinson's disease.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Karina Bienfait
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

8.  Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic.

Authors:  S Gulyani; R Salas; Z Mari; S Choi; A Mahajan; C Gamaldo
Journal:  Basal Ganglia       Date:  2016-05-27

Review 9.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

Review 10.  Treatment of Sleep Dysfunction in Parkinson's Disease.

Authors:  Amy W Amara; Lana M Chahine; Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2017-07       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.